Alvotech (ICE: ALVO)

Market Cap	500.33B
Revenue (ttm)	53.15B
Net Income (ttm)	-59.56B
Shares Out	n/a
EPS (ttm)	-235.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	502,210
Open	1,640.00
Previous Close	1,655.00
Day's Range	1,635.00 - 1,660.00
52-Week Range	1,200.00 - 2,500.00
Beta	-0.08
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 28, 2025

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 999
• Stock Exchange: Nasdaq Iceland
• Ticker Symbol: ALVO

Financial Performance

In 2023, Alvotech's revenue was $93.38 million, an increase of 9.84% compared to the previous year's $85.02 million. Losses were -$551.73 million, 7.43% more than in 2022.

Financial numbers in USD